Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0980 • ACR Convergence 2024
Ambient Air Pollution and Initiation of bDMARDs in Newly Diagnosed Rheumatoid Arthritis: A Nested Case-Control Study of NIH All of Us Cohort
Jiayi Zheng¹, Nevena Barjaktarovic² and Liangjing lu³, ¹Washington University School of Medicine, St. Louis, MO, ²The Wright Center for Community Health, South Abington Township, PA, ³Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic)
Background/Purpose: Ambient air pollution is a mixture of solid particles and gaseous pollutants derived from fossil fuel combustion and vehicle exhaust. Previous research has linked…
Abstract Number: 1037 • ACR Convergence 2024
Recommendations for the Perioperative Use of DMARDs in Rheumatic Diseases: A Scoping Review
Alice Terrett¹, Athena Chin², Mihye Kwon³, Samuel Whittle⁴ and Catherine Hill⁵, ¹The Queen Elizabeth Hospital, Adelaide, Australia, ²Royal Adelaide Hospital, Tranmere, South Australia, Australia, ³Konyang University, College of Medicine, Daejeon, Republic of Korea, ⁴The Queen Elizabeth Hospital, Springfield, South Australia, Australia, ⁵The Queen Elizabeth Hospital, Woodville, South Australia, Australia
Background/Purpose: The use of disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of autoimmune rheumatic diseases, including rheumatoid arthritis (RA), has significantly improved disease and functional…
Abstract Number: 1246 • ACR Convergence 2024
Long-Term Outcomes Based on the Sex of the Rheumatologist in a Prospective Cohort of RA Patients Receiving Biological Therapies
Alessandro Giollo¹, Mariangela Salvato², Margherita Zen³ and doria Andrea⁴, ¹Azienda Ospedale Università Padova, Padova, Padua, Italy, ²University of Padua, Padova, Italy, ³University of Padova, Padova, Padua, Italy, ⁴University of Padova, Padova, Italy
Background/Purpose: To explore the influence of the rheumatologist's sex on long-term outcomes in patients with rheumatoid arthritis (RA) undergoing biologic therapy.Methods: This is a prospective,…
Abstract Number: 1336 • ACR Convergence 2024
Risk of Malignancy Under the Treatments with Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: An Analysis Using Japanese Health Insurance Database
Ryoko Sakai¹, Eiichi Tanaka², Eisuke Inoue³ and Masayoshi Harigai⁴, ¹Meiji Pharmaceutical University, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ³Showa University, Tokyo, Japan, ⁴Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Janus kinase inhibitors (JAKIs) have shown positive therapeutic impacts on treatments for rheumatoid arthritis (RA), whereas, there are concerns about the risk of malignancy…
Abstract Number: 1352 • ACR Convergence 2024
The Associations Between Genetic Factors and Rheumatoid Arthritis Treatment Patterns: Data from Two Large Healthcare Systems
Gregory McDermott¹, Xin Xiong², Rachel Knevel³, Jing Cui⁴, Mary Jeffway⁴, Vidul Panickan⁵, Andrew Cagan⁴, Rahul Sangar⁶, Daniel Posner⁶, Lauren Costa⁶, Rachael Matty⁶, Elizabeth Karlson⁴, Yuk-Lam Ho⁶, Kelly Cho⁶, Rui Duan², Tianxi Cai² and Katherine Liao⁴, ¹Brigham and Women's Hospital, Brookline, MA, ²Harvard T.H. Chan School of Public Health, Boston, MA, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Harvard Medical School, Boston, MA, ⁶U.S. Department of Veterans Affairs, Boston, MA
Background/Purpose: In a prior study, we described an alternative method for subphenotyping RA patients by the sequence of biologic DMARDs (bDMARDs) they receive over time.…
Abstract Number: 1368 • ACR Convergence 2024
Do CsDMARDs Still Play a Significant Role in Managing Rheumatoid Arthritis in the Current Biologic/JAKI Era? A Prospective Observational Study to Estimate the Extent of Response to Conventional Synthetic DMARDs in RA– Experience from a Tertiary Care Center in South India
Prabhu Vasanth¹, John Mathew² and Divya K³, ¹Christian Medical college , Vellore , India, Vellore, Tamil Nadu, India, ²Christian Medical college , Vellore , India, Vellore, India, ³Christian Medical College, Vellore, Tamil Nadu, India
Background/Purpose: Conventional synthetic DMARDs remained the mainstay of treatment of RA for decades. However, their use has decreased recently due to the emergence of biological…
Abstract Number: 1385 • ACR Convergence 2024
A Novel Oral 3D-Printed Delayed- and Extended-Release Tofacitinib (T19) for the Treatment of Rheumatoid Arthritis and Related Inflammatory Diseases
Yue Zhou, Meng Ji, luo wang, Feihuang Deng, Senping Cheng, Xiaoling Li and Yulian Zhang, Triastek, Inc., Nanjing, China (People's Republic)
Background/Purpose: Patients with inflammatory diseases, such as rheumatoid arthritis (RA), frequently continue to suffer from morning symptoms despite treatment with conventional therapies 1,2. Routine morning…
Abstract Number: 1401 • ACR Convergence 2024
Risk of Malignancy with TNF-α Inhibitors in Patients with Rheumatoid Arthritis
Omair Khan¹, Syed Mujtaba Baqir², Azka Naeem², Muhammad Hashim khan², Tharun Shyam², Kseniya Slobodyanyuk³ and Anastasia Slobodnick⁴, ¹Maimonides Medical Center, Council Bluffs, IA, ²Maimonides Medical Center, Brooklyn, NY, ³Maimonides Medical Center, Manhattan, NY, ⁴Northwell, Staten Island, NY
Background/Purpose: Rheumatoid arthritis (RA) is associated with various comorbidities and complications among which cancer has been highlighted in literature. This cancer risk has been attributed…
Abstract Number: 1680 • ACR Convergence 2024
Reporting Quality of Non-inferiority and Equivalence Rheumatoid Arthritis Randomized Clinical Trials: A Systematic Review
Osama Alalwan¹ and Majeed Haider², ¹Salmaniya Medical Complex, Bahrain, Bahrain, ²Salmaniya Medical Complex, Manama, Bahrain
Background/Purpose: The number of non-inferiority/equivalence randomized clinical trials (NI/EQ-RCTs) in the rheumatoid arthritis (RA) field has recently increased for various reasons. These designs require special…
Abstract Number: 1840 • ACR Convergence 2024
Synovial Resident Memory T Cell Formation During Inflammation Requires Cell Contact with Fibroblast-Like Synoviocytes
Yusuke Miyashita¹, Yang Yang¹, Madison Mangin¹, Maryrose Hahn², Kevin Wei³, Peter Nigrovic⁴ and Margaret Chang¹, ¹Boston Children's Hospital, Boston, MA, ²Boston Children's Hospital, Georgetown, MA, ³Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁴Boston Children's Hospital, Brookline, MA
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by recurrent inflammation in the same joints, a feature termed joint-specific memory. We previously demonstrated…
Abstract Number: 1901 • ACR Convergence 2024
Venous Thromboembolism Risk Is Consistently Increased in People with Rheumatoid Arthritis Across Different Ages, Sexes and Obesity Status: United Kingdom Population Based Study
James Galloway¹, Victoria Basey², Michael Mclean², Simon de Lusignan³ and Maya H. Buch⁴, ¹Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ²Pfizer UK, Tadworth, United Kingdom, ³Royal College of General Practitioners Research and Surveillance Centre, Oxford, United Kingdom, ⁴Division of Musculoskeletal & Dermatological Sciences, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom
Background/Purpose: Risk of venous thromboembolism (VTE) is increased in people with rheumatoid arthritis (RA) when compared to the general population, but the variation of this…
Abstract Number: 2034 • ACR Convergence 2024
Effectiveness and Tolerability of Tocilizumab in Systemic Autoimmune Rheumatic Disease Associated Intertistial Lung Disease
Anne Dupont¹, Clairelyne Dupin², Esther Ebstein¹, Marine Forien¹, Sébastien Ottaviani¹, Pierre Le Guen², Quentin Philippot², Raphaël Borie², Bruno Crestani³, Philippe Dieudé¹ and Pierre-Antoine Juge⁴, ¹Departement of Rheumatology, AP-HP, Bichat Hospital, Paris, France, ²National Reference Center for Rare Pulmonary Diseases, Department of Pulmonology, AP-HP, Bichat Hospital, Paris, France, ³National Reference Center for Rare Pulmonary Diseases, Department of Pulmonology, AP-HP, Bichat Hospital, Paris, Ile-de-France, France, ⁴Departement of Rheumatology, AP-HP, Bichat Hospital, Boston, MA
Background/Purpose: Interstitial lung diseases (ILD) are severe manifestations of systemic autoimmune diseases (SARD) that are associated with an increased mortality. Although the primary endpoint was not…
Abstract Number: 2215 • ACR Convergence 2024
Treat (Depression to Reach)-to-Target in Rheumatoid Arthritis
Ozun Bayindir Tsechelidis¹, Ricardo Sabido-Sauri², Ummugulsum Gazel², Seyyid Bilal Acikgoz³, Sylvia Sangwa⁴, Catherine Ivory⁵, Elliot Hepworth² and Sibel Aydin⁶, ¹Ottawa University, Ottawa, ON, Canada, ²University of Ottawa, Ottawa, ON, Canada, ³University of Ottawa, Rheumatology, Ottawa, ON, Canada, ⁴The Ottawa Hospital Research Institute, Ottawa, Canada, ⁵The Ottawa Hospital, Ottawa, ON, Canada, ⁶University of Ottawa - Ottawa, Ottawa, ON, Canada
Background/Purpose: Depression is a prevalent comorbidity in Rheumatoid Arthritis (RA), affecting up to 38.8% of individuals. Depression can profoundly affect physical well-being, including increased pain…
Abstract Number: 2232 • ACR Convergence 2024
Anti-RA33 Autoantibodies Are Unique, Sensitive Biomarkers for the Identification of Seronegative Rheumatoid Arthritis in a U.S. Cohort
Andrew Concoff¹, Touba Warsi², Sepehr Taghavi², Sudha Kumar², Abigail Patalinghug², Christine Schleif², Brittany Partain³, Joseph Ahearn⁴, Nicole Wilson⁵, Susan Manzi⁵, Veena Joy⁶ and Tyler O'Malley⁷, ¹Exagen, Inc., Los Angeles, CA, ²Exagen, Carlsbad, CA, ³Exagen, Boston, MA, ⁴Allegheny Health Network, Wexford, PA, ⁵Allegheny Health Network, Pittsburgh, PA, ⁶ThermoFisher, Philadelphia, PA, ⁷Exagen, Vista, CA
Background/Purpose: Novel autoantibodies (Ab) capable of identifying unique subgroups of seronegative rheumatoid arthritis (SN-RA) while providing specificity for RA comparable to ACPA reflects an opportunity…
Abstract Number: 2249 • ACR Convergence 2024
Assessment of Interstitial Lung Disease in Rheumatoid Arthritis Patients Treated with JAK Inhibitors: A National Multicenter Observational Study from the MAJIK-SFR Registry
Felicien Triboulet¹, Pierre-Antoine Juge², Marie-Elise Truchetet³, Thao Pham⁴, nicolas Roux⁵, Rene-Marc Flipo⁶, Charles Leske⁷, christian roux⁸, Raphaele Seror⁹, Andre Basch¹⁰, OLIVIER BROCQ¹¹, Pascal Chazerain¹², Fabienne Coury-Lucas¹³, Richard Damade¹⁴, Emmanuelle Dernis¹⁵, Jacques-Eric Gottenberg¹⁶, Andre Ramon¹⁷, Adeline Ruyssen-Witrand¹⁸, Jean-Hugues Salmon¹⁹, Emilie Shipley²⁰, Anne Tournadre²¹, CLEMENT PRATI²², Philippe Dieudé²³ and Jérôme Avouac²⁴, and and MAJIK -SFR registry investigators, ¹Service de Rhumatologie, hôpital Cochin, Paris, France, ²Departement of Rheumatology, AP-HP, Bichat Hospital, Boston, MA, ³Bordeaux University Hospital, Bordeaux, France, ⁴Assistance Publique-Hôpitaux de Marseille, Marseille, France, ⁵5Service de Rhumatologie, hôpital Robert-Schuman, Université de Lorraine, Metz, France, ⁶Service de Rhumatologie, hôpital Roger-Salengro, Université de Lille, Lille, France, ⁷Service de Rhumatologie, centre hospitalier de Cholet, Université d’Angers, Cholet, France, ⁸rheumatology department, university Cote d'Azur, nice, France, ⁹Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, ¹⁰Service de Rhumatologie, clinique de l'Infirmerie Protestante, Lyon, France, ¹¹Service de Rhumatologie, centre hospitalier Princesse-Grâce, Monaco, Monaco, ¹²Service de Rhumatologie, groupe hospitalier Diaconnesses - Croix-Saint-Simon, Paris, France, ¹³Service de Rhumatologie, hôpital Lyon-Sud, Université Claude-Bernard Lyon I, Hospices Civils de Lyon, Lyon, France, ¹⁴Service de Rhumatologie, hôpital Louis-Pasteur, Université d’Orléans, Chartres, France, ¹⁵CH LE MANS, LE MANS, Pays de la Loire, France, ¹⁶Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ¹⁷Dijon University Hospital, Besançon, France, ¹⁸Toulouse University Hospital, Toulouse, France, ¹⁹Service de Rhumatologie, centre hospitalier universitaire de Reims, Université de Reims Champagne-Ardenne, Reims, France, ²⁰Service de Rhumatologie, centre hospitalier Dax-Côte d’Argent, Université de Bordeaux, Dax, France, ²¹Service de Rhumatologie, centre hospitalier universitaire de Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, France, ²²Service de Rhumatologie, centre hospitalier régional universitaire Jean-Minjoz, Université de Franche-Comté, Besançon, France, ²³Departement of Rheumatology, AP-HP, Bichat Hospital, Paris, France, ²⁴Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: The available data on the impact of JAK inhibitors (JAKi) on rheumatoid arthritis-associated interstitial lung disease (RA-ILD) are currently limited. This study aimed to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].